NCT01413932View on ClinicalTrials.gov

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Healthy Volunteers (Part 1)Major Depressive Disorder (Part 2)
Interventions
DRUG

HT-2157

QD oral dosing

DRUG

Placebo

QD oral dosing

Trial Locations (1)

91206

Clinical Site, Glendale

Sponsors
All Listed Sponsors
lead

Dart NeuroScience, LLC

INDUSTRY

NCT01413932 - Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder | Biotech Hunter | Biotech Hunter